Global Fund's interim quality assurance policy multi-source products
The governing Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has decided that its quality assurance policy for all pharmaceutical products will be reviewed and a report of review will be submitted to the Board at its 18th meeting in November 2008. In the meantime, the Board has decided to set up an interim quality assurance policy for multi-source products. It took this action in order to address concerns raised about the risk of quality assurance problems with drugs previously covered by the Global Fund's quality assurance policy for single and limited source products that have recently been re-categorized as multi-source products. As an interim measure to address this risk pending the outcome of the review of quality assurance policy, the Board decides that any drugs for the treatment of HIV/AIDS, TB and malaria for which the formula has been published since the 3rd Board Meeting (October 2002) shall be subject to the single and limited source quality assurance policy. This change will take effect immediately (13 November 2007).